# MK-3475-03A (NCT04626479)

> Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab/quavonlimab plus lenvatinib; favezelimab/pembrolizumab plus lenvatinib; belzutifan plus pembrolizumab plus lenvatinib
- Indication: first-line advanced clear-cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04626479
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Pembrolizumab; Favezelimab/Pembrolizumab; Belzutifan; Lenvatinib; Pembrolizumab/Quavonlimab; Vibostolimab/Pembrolizumab
- Enrollment: 393
- Primary outcome: Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
- Primary outcome: Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)
- Primary outcome: Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE
- Primary outcome: Efficacy Phase: Number of participants who experience one or more DLTs
- Primary outcome: Efficacy Phase: Number of participants who experience one or more AEs
- Primary outcome: Efficacy Phase: Number of participants who discontinue study treatment due to an AE
- Primary outcome: Efficacy Phase: Objective response rate (ORR)

## Indexed commentary on MK-3475-03A so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mk-3475-03a-nct04626479